Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Sudden collapse, sometimes followed by death, still occurs during the administration of quinidine, in spite of selection of cases by criteria that are now widely accepted. Post-mortem examinations show in some cases an embolism in some vital organ, but in others no obvious cause of death can be found. The object of this investigation was to throw some light on the cause of death in these patients and to suggest possible remedies.Observations have been made on patients who collapsed while receiving quinidine and on the electrocardiogram of patients who, although receiving quinidine, showed no toxic effects from the drug: finally, a certain number of experiments were carried out on animals to supplement the observations on man. OBSERVATIONS ON MANAmong 115 patients treated with quinidine in the last six years at Guy's Hospital for cardiac arrhythmias there have been one fatal and two severe reactions.Case 1. Mrs. O., aged 28, had a successful mitral valvotomy and was left with minimal aortic stenosis. Two years later she developed auricular fibrillation and after preliminary control by digoxin, which was then omitted for two days, she was given quinidine, 0-2 g. stat. and 0-2 g. two-hourly. After a total of 1 2 g. she reverted to sinus rhythm and the quinidine was stopped when she had taken a total of 1-4 g. Half an hour later she became acutely distressed with signs of congestive cardiac failure. A cardiogram at this time ( Fig. 1) showed bradycardia, with a shifting pacemaker. She died suddenly a few minutes later. Necropsy revealed no cause of death.Case 2. Mrs. P., aged 55, developed auricular fibrillation without apparent cause. This was controlled by digoxin, which was then omitted for one day. She was then given quinidine, 0-3 g. on the first day, 0-6 g. on the second, 1 g. on the third and 1 3 g. on the fourth day. Immediately following the final dose on the fourth day the patient collapsed with dyspnoeic and generalized convulsions. Two hours later she again collapsed; the pulse disappeared and the heart sounds were inaudible for three minutes. She was then given I ml. of 1: 1000 adrenaline by intracardiac injection and the heart began to beat. A cardiogram taken a few minutes later showed sinus rhythm with prolongation of the P-R interval (0-22 sec.) and widening of the QRS complexes (0-12 sec.). Her blood pressure was 80/40. Following methyl amphetamine 10 mg. intramuscularly it rose to 90/66 and after a further 10 mg. of the same drug to 110/80. By next morning she had recovered. Case 3. Mrs. W., aged 25, had a successful mitral valvotomy. Following operation she was troubled by attacks of palpitation. She was admitted to Guy's Hospital a year later and was found to have auricular flutter with varying A-V block. This was converted to auricular fibrillation by digoxin and 24 hours after. stopping this drug she was given quinidine. She received 1 6 g. the first day and reverted to sinus rhythm. The following day, three hours after receiving a maintenance dose of 0-3 g. of quinidine, she developed a furthe...
Sudden collapse, sometimes followed by death, still occurs during the administration of quinidine, in spite of selection of cases by criteria that are now widely accepted. Post-mortem examinations show in some cases an embolism in some vital organ, but in others no obvious cause of death can be found. The object of this investigation was to throw some light on the cause of death in these patients and to suggest possible remedies.Observations have been made on patients who collapsed while receiving quinidine and on the electrocardiogram of patients who, although receiving quinidine, showed no toxic effects from the drug: finally, a certain number of experiments were carried out on animals to supplement the observations on man. OBSERVATIONS ON MANAmong 115 patients treated with quinidine in the last six years at Guy's Hospital for cardiac arrhythmias there have been one fatal and two severe reactions.Case 1. Mrs. O., aged 28, had a successful mitral valvotomy and was left with minimal aortic stenosis. Two years later she developed auricular fibrillation and after preliminary control by digoxin, which was then omitted for two days, she was given quinidine, 0-2 g. stat. and 0-2 g. two-hourly. After a total of 1 2 g. she reverted to sinus rhythm and the quinidine was stopped when she had taken a total of 1-4 g. Half an hour later she became acutely distressed with signs of congestive cardiac failure. A cardiogram at this time ( Fig. 1) showed bradycardia, with a shifting pacemaker. She died suddenly a few minutes later. Necropsy revealed no cause of death.Case 2. Mrs. P., aged 55, developed auricular fibrillation without apparent cause. This was controlled by digoxin, which was then omitted for one day. She was then given quinidine, 0-3 g. on the first day, 0-6 g. on the second, 1 g. on the third and 1 3 g. on the fourth day. Immediately following the final dose on the fourth day the patient collapsed with dyspnoeic and generalized convulsions. Two hours later she again collapsed; the pulse disappeared and the heart sounds were inaudible for three minutes. She was then given I ml. of 1: 1000 adrenaline by intracardiac injection and the heart began to beat. A cardiogram taken a few minutes later showed sinus rhythm with prolongation of the P-R interval (0-22 sec.) and widening of the QRS complexes (0-12 sec.). Her blood pressure was 80/40. Following methyl amphetamine 10 mg. intramuscularly it rose to 90/66 and after a further 10 mg. of the same drug to 110/80. By next morning she had recovered. Case 3. Mrs. W., aged 25, had a successful mitral valvotomy. Following operation she was troubled by attacks of palpitation. She was admitted to Guy's Hospital a year later and was found to have auricular flutter with varying A-V block. This was converted to auricular fibrillation by digoxin and 24 hours after. stopping this drug she was given quinidine. She received 1 6 g. the first day and reverted to sinus rhythm. The following day, three hours after receiving a maintenance dose of 0-3 g. of quinidine, she developed a furthe...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.